HIV molecular immunology database
DLRNLCLFSYHRLRDLL
|
gp160(759-775) | human epitope |
LFSYHRLRDLLLIVTRIV
|
gp160(765-782) | human epitope |
LFSYHRLRDLLLIVTRIV
|
gp160(765-782) | human epitope |
LFrYHRLRDLLLIVTRIV
|
gp160(765-782) | observed variant |
LFSYHRLRDLLLIVARIV
|
gp160(765-782) | human epitope |
SYRRLRDLL
|
gp160(767-775) | A*24:02 human epitope |
SYHRLRDFI
|
gp160(767-775) | H-2Kd mouse epitope |
SYHRLRDFv
|
gp160(767-775) | susceptible form |
SYHRLRDcI
|
gp160(767-775) | diminished response |
SYHRLRDll
|
gp160(767-775) | diminished response |
SYHRLRDlI
|
gp160(767-775) | diminished response |
SYrhLRDFI
|
gp160(767-775) | non-susceptible form |
iYHhLRDll
|
gp160(767-775) | non-susceptible form |
SYrlLRDll
|
gp160(767-775) | non-susceptible form |
SYHRLRDFI
|
gp160(767-775) | H-2d human, mouse epitope |
SYHRLRDLLLIVTR
|
gp160(767-780) | A3, A31 human epitope |
SYHRLRDLLLIVTR
|
gp160(767-780) | A31 human epitope |
YHQLRDFILIVARTV
|
gp160(768-782) | A*03:01, A*31:01 human epitope |
YHrLRDFllIVtRTV
|
gp160(768-782) | non-susceptible form |
HRLRDLLLI
|
gp160(769-777) | B*27:02 human epitope |
HRLRDLLLI
|
gp160(769-777) | B*27:05 human epitope |
HRLRDLLLI
|
gp160(769-777) | human epitope |
RLRDLLLIV
|
gp160(770-778) | A*02 human epitope |
RLRDLLLIV
|
gp160(770-778) | A*02:01 human epitope |
RLRDLLLIV
|
gp160(770-778) | A*02:01 human epitope |
RLRDLLLIV
|
gp160(770-778) | A2 transgenic mouse epitope |
RLRDLLLIV
|
gp160(770-778) | human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*03 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*03 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*03 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*03 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*03 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*03:01 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*03:01 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*03:01 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A3 human epitope |
RLRDfiLIVTR
|
gp160(770-780) | diminished response; subtype-specific susceptible form |
SLRDLLLIVTR
|
gp160(770-780) | diminished response; subtype-specific susceptible form |
RLRDLLLIVTR
|
gp160(770-780) | A3 human epitope |
RLRDLLLIiTR
|
gp160(770-780) | observed variant |
RLRDLLLvVTR
|
gp160(770-780) | observed variant |
RLRDLLLIVTR
|
gp160(770-780) | A3 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A3 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A3, A31 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A3, A31 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A3, A31 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*31 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A31 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A31 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A31 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*31:01 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*31:01 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*34 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | A*74 human epitope |
RLRDLLLIVTR
|
gp160(770-780) | human epitope |
RLRDLLLIVTR
|
gp160(770-780) | human epitope |
DFILIVARTVELLGH
|
gp160(773-787) | A*68:02 human epitope |
DFILIVtRiVELLGH
|
gp160(773-787) | non-susceptible form |
IVTRIVELL
|
gp160(777-785) | A*02:05 human epitope |
IVTRIVELL
|
gp160(777-785) | A68 human epitope |
IVTRIVELL
|
gp160(777-785) | A*68:02 human epitope |
IVTRIVELL
|
gp160(777-785) | B*15:17 human epitope |
IVTRIVELL
|
gp160(777-785) | B*40 human epitope |
IVTRIVELL
|
gp160(777-785) | C*01 human epitope |
IVTRIVELL
|
gp160(777-785) | C*18 human epitope |